Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest

PHASE2CompletedINTERVENTIONAL
Enrollment

361

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

November 30, 2018

Study Completion Date

May 31, 2019

Conditions
Labor, Obstetric
Interventions
DRUG

DF 01

DRUG

Oxytocin

DRUG

Placebo

Trial Locations (12)

2650

Hvidovre Hospital, Fødeafdelingen, Hvidovre

25187

Helsingborg Förlossningen, Helsingborgs Lasarett, Helsingborg

33521

Tampere University Hospital, Tampere

46173

Norra Älvsborgs Länssjukhus, Trollhättan

54185

Skaraborgs sjukhus, Skövde

55305

Länssjukhuset Ryhov, Jönköping

58185

Kvinnokliniken Universitesjukhuset, Linköping

60182

Kvinnokliniken Vrinnevisjukhuset, Norrköping

65230

Karlstad Kvinnokliniken Centralsjukhuset, Karlstad

75185

Akademiska sjukhuset, Uppsala

00029

Naistenklinikka (HUS) Naistentaudit ja synnytykset, Helsinki

00610

Kätilöopiston Sairaala (HUS), Helsinki

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dilafor AB

INDUSTRY

NCT03001193 - Effect of Tafoxiparin to Treat Primary Slow Progress of Labor Including Prolonged Latent Phase and Labor Arrest | Biotech Hunter | Biotech Hunter